GNI Group Projects Record Sales and Profits Amid U.S.-China Tariff Concerns

An announcement from GNI Group ( (JP:2160) ) is now available.

GNI Group has announced its business outlook for 2025, highlighting record-high sales and operating profits in its pharma segment, driven by new drug introductions and a recovery from the previous year. The company expects minimal impact from U.S.-China trade tariffs due to its established operations in China. In the drug discovery segment, despite the U.S.-China tariff conflicts, the company forecasts a strong operating profit due to other income from accrued interest elimination. The med-tech segment anticipates potential tariff impacts but plans to mitigate these through price increases, aiming for record sales and profits in 2025.

More about GNI Group

GNI Group Ltd. operates in the pharmaceutical, drug discovery, and med-tech industries, focusing on research and development, manufacturing, and sales of therapeutic drugs. The company has a significant presence in China and includes subsidiaries such as GYRE Pharmaceuticals and Cullgen Inc.

YTD Price Performance: -51.42%

Average Trading Volume: 1,396

Technical Sentiment Signal: Strong Buy

Current Market Cap: €545M

For a thorough assessment of 2160 stock, go to TipRanks’ Stock Analysis page.